A multi-institutional research team has developed one of the first validated tools to predict before treatment if a patient will have a favorable biochemical response in patients with metastatic hormone-sensitive prostate cancer.
Prostate cancer remains a formidable challenge, particularly in its advanced stages, where bone metastases and treatment resistance dominate outcomes. At City of Hope, our focus is on leveraging immunotherapy to transform this landscape.
